FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA notice of a supplemental application for CRESEMBA (isavuconazonium sulfate) submitted by Astellas Pharma US, Inc., indicating a potential labeling change.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis
• Mucormycosis

Drugs mentioned

• Cresemba (isavuconazole)

Snippet

SUPPL AP for CRESEMBA (ISAVUCONAZONIUM SULFATE)